Limits...
Programmed chemotherapy for patients with metastatic unresectable gastric cancer.

Shinoda M, Ando T, El-Omar EM, Takashi H, Suzuki T, Murayama M, Morise K, Goto H - PLoS ONE (2012)

Bottom Line: Grade 3-4 toxicities were neutropenia in 12% and anorexia in 6%.All treatment- related toxicities were resolved, and no treatment-related deaths occurred.This program provided reasonable selection of case-matching regimens and may improve the survival of patients with MGC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ABSTRACT

Background: Recent advances in the treatment of metastatic unresectable gastric cancers (MGC) include the development of new antitumor drugs and new regimens for their use. However, the selection of individually designed regimens by gastric cancer (GC) subtype remains problematic. Here, we investigated the clinical usefulness of programmed chemotherapy.

Methodology/principal findings: MGC patients were classified into three groups by clinical condition. We implemented a chemotherapy program consisting of S-1 combination regimens. Median survival time (MST) of level 1 patients was 416 days (95% CI: 313-506 days), with an overall response rate of 47%. MSTs of level 2 and 3 patients were 208 (95% CI: 153-287 days) and 95 days (95% CI: 28-136 days), respectively. Grade 3-4 toxicities were neutropenia in 12% and anorexia in 6%. All treatment- related toxicities were resolved, and no treatment-related deaths occurred.

Conclusions/significance: This program provided reasonable selection of case-matching regimens and may improve the survival of patients with MGC. Further, it may represent the first clinical tool to provide efficient chemotherapy course selection for MGC. Ongoing analysis of newly developed drugs and regimens will allow the efficacy of this chemotherapy program to be improved.

Show MeSH

Related in: MedlinePlus

Correlation between treatment time and OS.A good correlation was seen between treatment time and survival time.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3383684&req=5

pone-0038652-g003: Correlation between treatment time and OS.A good correlation was seen between treatment time and survival time.

Mentions: The survival curve of each level is shown in Figure 2. Median survival time (MST) of level 1 patients was 416 days (95% CI: 313–506 days), with an overall response rate of 47%. MSTs of level 2 and 3 patients were 208 (95% CI: 153–287 days) and 95 days (95% CI: 28–136 days), respectively. With regard to the outcome of level 1 patients, all 3 subgroups showed an MST of 13 months or more (Table 1). Further, the relationship between treatment time and OS correlated well, except in one complete response (CR) case (Figure 3).


Programmed chemotherapy for patients with metastatic unresectable gastric cancer.

Shinoda M, Ando T, El-Omar EM, Takashi H, Suzuki T, Murayama M, Morise K, Goto H - PLoS ONE (2012)

Correlation between treatment time and OS.A good correlation was seen between treatment time and survival time.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3383684&req=5

pone-0038652-g003: Correlation between treatment time and OS.A good correlation was seen between treatment time and survival time.
Mentions: The survival curve of each level is shown in Figure 2. Median survival time (MST) of level 1 patients was 416 days (95% CI: 313–506 days), with an overall response rate of 47%. MSTs of level 2 and 3 patients were 208 (95% CI: 153–287 days) and 95 days (95% CI: 28–136 days), respectively. With regard to the outcome of level 1 patients, all 3 subgroups showed an MST of 13 months or more (Table 1). Further, the relationship between treatment time and OS correlated well, except in one complete response (CR) case (Figure 3).

Bottom Line: Grade 3-4 toxicities were neutropenia in 12% and anorexia in 6%.All treatment- related toxicities were resolved, and no treatment-related deaths occurred.This program provided reasonable selection of case-matching regimens and may improve the survival of patients with MGC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ABSTRACT

Background: Recent advances in the treatment of metastatic unresectable gastric cancers (MGC) include the development of new antitumor drugs and new regimens for their use. However, the selection of individually designed regimens by gastric cancer (GC) subtype remains problematic. Here, we investigated the clinical usefulness of programmed chemotherapy.

Methodology/principal findings: MGC patients were classified into three groups by clinical condition. We implemented a chemotherapy program consisting of S-1 combination regimens. Median survival time (MST) of level 1 patients was 416 days (95% CI: 313-506 days), with an overall response rate of 47%. MSTs of level 2 and 3 patients were 208 (95% CI: 153-287 days) and 95 days (95% CI: 28-136 days), respectively. Grade 3-4 toxicities were neutropenia in 12% and anorexia in 6%. All treatment- related toxicities were resolved, and no treatment-related deaths occurred.

Conclusions/significance: This program provided reasonable selection of case-matching regimens and may improve the survival of patients with MGC. Further, it may represent the first clinical tool to provide efficient chemotherapy course selection for MGC. Ongoing analysis of newly developed drugs and regimens will allow the efficacy of this chemotherapy program to be improved.

Show MeSH
Related in: MedlinePlus